Want a robust quality drug pipeline? – Pay super premium!: Alexion to acquire Synageva in an $8.4bn deal

Alexion Pharmaceuticals Inc.; market cap (as of 09/05/2015): $32.54bn Synageva Biopharma Corp.; market cap (as of 09/05/2015): $7.91bn   Introduction On May 6, 2015, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), the manufacturer of the world’s single most expensive prescription drug Soliris, and Synageva BioPharma Corp. (NASDAQ:GEVA) have entered into a definitive agreement Read more…

Bayer acquires Merck’s consumer care business for an eye-catching price

Bayer AG Market Cap (09/05/2014): $115.17bn Merck & Co., Inc. Market Cap (09/05/2014): $161.23bn On May 6th, Bayer announced the acquisition of Merck’s consumer care business for a hefty $14.2bn, surpassing competing offers from Boehringer-Ingelheim and Reckitt Benckiser and, thus becoming the second largest company in over-the-counter (OTC) products worldwide. Read more…

Actavis and Forest Laboratories are going to create a long-term powerful “engine”

Actavis Plc, Market Cap (as of 21/02/14): $38.35bn Forest Laboratories Inc, Market Cap (as of 21/02/14): $26.36bn On February 18th, 2014 the Dublin-based generic drug maker, Actavis PLC, announced an acquisition of the New York-based specialty drug maker, Forest Laboratories Inc, in a $25bn cash-and-equity deal. If successfully completed, the Read more…